Jennifer R. Eads, MD

Capdevila J, Artamonova E, De Jesus Acosta A, Niccoli P, Toth M, Ramirez R, Hendifar A, Cingarlini S, Trikalinos NA, Quante M, Garcia-Carbonero R, Goder E, del Rivero J, Eads JR, Odeleye-Ajakaye A, Gozman A, Naik GS, Spada F Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase 2 LITESPARK-015 study , European Society of Medical Oncology Annual Meeting: 2025

Eads JR, Morelli MP, Olson D, Litten JB, Astrow SH, Pelster M A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers , J Clin Oncol: 2025

Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Fivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland J, Tabernero J, MATTERHORN Investigators Perioperative durvalumab in gastric and gastroesophageal junction cancer , N Engl J Med: 2025

Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O’Hara MH, Eads JR, King D, Shah MM, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA Incorporating circulating tumor DNA testing into clinical trials: a position paper by the National Cancer Institute GI Oncology circulating tumor DNA working group , JCO Precision Oncology: 2025

Eads JR Episode 26: Neuroendocrine Neoplasms: Focus on Immunotherapy , Los Angeles Carcinoid Neuroendocrine Tumor Foundation Podcast: 2024

Wornow S, DePietro D, Eads JR, Roses R, Soulen MC To treat or not to treat: resection of primary pancreatic neuroendocrine tumors in the metastatic setting , North American Neuroendocrine Tumor Society Annual Meeting: 2024

D’Souza JC, van Houten D, Reiss KA, Cohen RB, Kosteva JA, Schneider CJ, Eads JR, Teitelbaum UR, Soulen MC Initial outcomes of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 3 liver-dominant metastatic neuroendocrine tumors , North American Neuroendocrine Tumor Society Annual Meeting: 2024

Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padron LJ, Maurer DM, Yu JX, Spencer CN, Gherardini PF, Da Silva DM, LaVallee TM, Abbott C, Chen RO, Boyle SM, Bhagwat N, Cannas S, Sagreiya H, Li W, Yee SS, Abdalla A, Wang Z, Yin M, Ballinger D, Wissel P, Eads J, Karasic, Schneider C, O’Dwyer P, Teitelbaum U, Reiss KA, Rahma OE, Fisher GA, Ko AH, Wainberg ZA, Wolff RA, O’Reilly EM, O’Hara MH, Cabanski CR, Vonderheide RH, Carpenter EL Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma , Nat Communication: 2024

Chapin WJ, Massa R, Eads JR Defining the role of neoadjuvant therapy for gastroesophageal cancers , Advances in Oncology: 2024

Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O’Dwyer PJ A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174) , J Clin Oncol: 2024